Figure 4

Survival of patients receiving either non-anthracycline-based therapy or anthracycline-based chemotherapy. (a) The difference between patients with less than 25% positive cells for topoisomerase IIα (dashed lines) and more than 25% positive cells (solid lines) was significant for both patient groups (P < 0.05). (b) Significant difference between patients with (solid line) or without (dashed line) c-erbB2 overexpression in the group of patients receiving non-anthracycline-based adjuvant therapy (left panel; P = 0.002) or an anthracycline-containing regimen (right panel; P = 0.001)